TREM1 is involved in the mechanism between asthma and lung cancer by regulating the Toll‑like receptor signaling pathway

Yan,Zhulin; Zhang,Wei; Sun,Keyu

doi:10.3892/ol.2023.14149

TREM1 is involved in the mechanism between asthma and lung cancer by regulating the Toll‑like receptor signaling pathway

Authors:
- Zhulin Yan
- Wei Zhang
- Keyu Sun
View Affiliations

Affiliations: Department of Emergency Medicine, Minhang Hospital, Fudan University, Shanghai 201100, P.R. China
Published online on: November 13, 2023 https://doi.org/10.3892/ol.2023.14149
Article Number: 16
Copyright: © Yan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer and asthma are both global health problems with significant economic consequences. Recent studies have demonstrated that asthma may be a risk factor for lung cancer. The present study aimed to explore the pathogenesis between these two diseases through a comprehensive analysis. Differentially expressed genes (DEGs) screened in the asthma‑related GSE165934 dataset were analyzed to find relevant inflammatory pathways. Overlapping genes regulated by inflammatory pathways and lung cancer‑DEGs from The Cancer Genome Atlas (TCGA) were obtained and subjected to survival and gene‑wide mutation analyses, and nomogram construction to determine the hub gene. The hub gene was further analyzed through expression validation, immunoassays and functional experiments to investigate its role and mechanism in lung cancer. Functional enrichment analysis showed that 1,275 DEGs from GSE165934 were closely associated with the Toll‑like receptor signaling pathway, and 8 overlapping genes were identified from 12 genes regulated by the Toll‑like receptor signaling pathway and 3,134 TCGA‑DEGs. After a series of bioinformatics analyses, it was found that triggering receptor expressed on myeloid cells 1 (TREM1) was the hub gene involved in the mechanism of asthma and lung cancer. TREM1 was also found to be a suppressor gene in lung cancer correlated with immune cells, immune checkpoint‑related genes and tumor mutational burden score. Additionally, the results of Cell Counting Kit‑8 and Transwell experiments demonstrated that overexpression of TREM1 could significantly inhibit the invasion, proliferation and migration of lung cancer cells. Reverse transcription‑quantitative PCR and western blotting demonstrated that the overexpression of TREM1 could also significantly reduce the level of Toll‑like receptor signaling pathway proteins. The present findings suggest that TREM1 is associated with the mechanism of asthma and lung cancer through its regulation of the Toll‑like receptor signaling pathway. Furthermore, TREM1 may serve as a potential treatment target and prognostic indicator for patients with lung cancer.

View Figures

View References

1	Dorantes-Heredia R, Ruiz-Morales JM and Cano-Garcia F: Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors. Transl Lung Cancer Res. 5:401–412. 2016. View Article : Google Scholar : PubMed/NCBI
2	Buttery R, Monaghan H, Salter DM and Sethi T: Galectin-3: Differential expression between small-cell and non-small-cell lung cancer. Histopathology. 44:339–344. 2010. View Article : Google Scholar
3	Santillan AA, Camargo CA Jr and Colditz GA: A meta-analysis of asthma and risk of lung cancer (United States). Cancer Causes Control. 14:327–334. 2003. View Article : Google Scholar : PubMed/NCBI
4	Qu YL, Liu J, Zhang LX, Wu CM, Chu AJ, Wen BL, Ma C, Yan XY, Zhang X, Wang DM, et al: Asthma and the risk of lung cancer: A meta-analysis. Oncotarget. 8:11614–11620. 2017. View Article : Google Scholar : PubMed/NCBI
5	Stading R, Gastelum G, Chu C, Jiang W and Moorthy B: Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer. Semin Cancer Biol. 76:3–16. 2021. View Article : Google Scholar : PubMed/NCBI
6	Rosenberger A, Bickeböller H, McCormack V, Brenner DR, Duell EJ, Tjønneland A, Friis S, Muscat JE, Yang P, Wichmann HE, et al: Asthma and lung cancer risk: A systematic investigation by the international lung cancer consortium. Carcinogenesis. 33:587–597. 2012. View Article : Google Scholar : PubMed/NCBI
7	Jiang L, Sun YQ, Langhammer A, Brumpton BM, Chen Y, Nilsen T, Leivseth L, Wahl SGF and Mai XM: Asthma and asthma symptom control in relation to incidence of lung cancer in the HUNT study. Sci Rep. 11:45392021. View Article : Google Scholar : PubMed/NCBI
8	Denholm R, Schüz J, Straif K, Stücker I, Jöckel KH, Brenner DR, De Matteis S, Boffetta P, Guida F, Brüske I, et al: Is previous respiratory disease a risk factor for lung cancer? Am J Respir Crit Care Med. 190:549–559. 2014. View Article : Google Scholar : PubMed/NCBI
9	Garth J, Barnes J and Krick S: Targeting cytokines as evolving treatment strategies in chronic inflammatory airway diseases. Int J Mol Sci. 19:34022018. View Article : Google Scholar : PubMed/NCBI
10	Toskala E and Kennedy DW: Asthma risk factors. Int Forum Allergy Rhinol. 5:S11–S16. 2015. View Article : Google Scholar : PubMed/NCBI
11	Bjorksten B: Genetic and environmental risk factors for the development of food allergy. Curr Opin Allergy Clin Immunol. 5:249–253. 2005. View Article : Google Scholar : PubMed/NCBI
12	Hunt LW, Frigas E, Butterfield JH, Kita H, Blomgren J, Dunnette SL, Offord KP and Gleich GJ: Treatment of asthma with nebulized lidocaine: A randomized, placebo-controlled study. J Allergy Clin Immunol. 113:853–859. 2004. View Article : Google Scholar : PubMed/NCBI
13	Zhu Y, Davis S, Stephens R, Meltzer PS and Chen Y: GEOmetadb: Powerful alternative search engine for the Gene Expression Omnibus. Bioinformatics. 24:2798–2800. 2008. View Article : Google Scholar : PubMed/NCBI
14	Wen S, Li F, Tang Y, Dong L, He Y, Deng Y and Tao Z: MIR222HG attenuates macrophage M2 polarization and allergic inflammation in allergic rhinitis by targeting the miR146a-5p/TRAF6/NF-κB axis. Front Immunol. 14:11689202023. View Article : Google Scholar : PubMed/NCBI
15	Simonson MA, Mcqueen MB and Keller MC: Plot generated using STRING 9.0 (Search Tool for the Retrieval of Interacting Genes). 2014.
16	Kohl M, Wiese S and Warscheid B: Cytoscape: Software for visualization and analysis of biological networks. Methods Mol Biol. 696:291–303. 2011. View Article : Google Scholar : PubMed/NCBI
17	Xu Y, Shu D, Shen M, Wu Q, Peng Y, Liu L, Tang Z, Gao S, Wang Y and Liu S: Development and validation of a novel PPAR signaling pathway-related predictive model to predict prognosis in breast cancer. J Immunol Res. 2022:94121192022. View Article : Google Scholar : PubMed/NCBI
18	Zeng Z, Yu J, Yang Z, Du K, Chen Y and Zhou L: Investigation of M2 macrophage-related gene affecting patients prognosis and drug sensitivity in non-small cell lung cancer: Evidence from bioinformatic and experiments. Front Oncol. 12:10964492022. View Article : Google Scholar : PubMed/NCBI
19	Zhang W, Hong HJ and Chen YL: Establishment of a gallbladder cancer-specific survival model to predict prognosis in non-metastatic gallbladder cancer patients after surgical resection. Dig Dis Sci. 63:2251–2258. 2018. View Article : Google Scholar : PubMed/NCBI
20	Wu ZH and Yang DL: High CENPM mRNA expression and its prognostic significance in hepatocellular carcinoma: A study based on data mining. Cancer Cell Int. 20:4062020. View Article : Google Scholar : PubMed/NCBI
21	Zhang Q, Xia T, Qi C, Du J and Ye C: High expression of S100A2 predicts poor prognosis in patients with endometrial carcinoma. BMC Cancer. 22:772022. View Article : Google Scholar : PubMed/NCBI
22	Li B, Li T, Liu JS and Liu XS: Computational deconvolution of tumor-infiltrating immune components with bulk tumor gene expression data. Methods Mol Biol. 2120:249–262. 2020. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Sistek D, Tschopp JM, Schindler C, Brutsche M, Ackermann-Liebrich U, Perruchoud AP and Leuenberger P: Clinical diagnosis of current asthma: Predictive value of respiratory symptoms in the SAPALDIA study. Swiss study on air pollution and lung diseases in adults. Eur Respir J. 17:214–219. 2001. View Article : Google Scholar : PubMed/NCBI
25	Hom S and Pisano M: Reslizumab (Cinqair): An interleukin-5 antagonist for severe asthma of the eosinophilic phenotype. P T. 42:564–568. 2017.PubMed/NCBI
26	van der Vliet A, Janssen-Heininger YMW and Anathy V: Oxidative stress in chronic lung disease: From mitochondrial dysfunction to dysregulated redox signaling. Mol Aspects Med. 63:59–69. 2018. View Article : Google Scholar : PubMed/NCBI
27	Henderson I, Caiazzo E, McSharry C, Guzik TJ and Maffia P: Why do some asthma patients respond poorly to glucocorticoid therapy? Pharmacol Res. 160:1051892020. View Article : Google Scholar : PubMed/NCBI
28	Barnes PJ: Efficacy of inhaled corticosteroids in asthma. J Allergy Clin Immunol. 102:531–538. 1998. View Article : Google Scholar : PubMed/NCBI
29	Raissy HH, Kelly HW, Harkins M and Szefler SJ: Inhaled corticosteroids in lung diseases. Am J Respir Crit Care Med. 187:798–803. 2013. View Article : Google Scholar : PubMed/NCBI
30	Miller LS: Toll-like receptors in skin. Adv Dermatol. 24:71–87. 2008. View Article : Google Scholar : PubMed/NCBI
31	Kaisho T and Akira S: Toll-like receptor function and signaling. J Allergy Clin Immunol. 117:979–987. 2006. View Article : Google Scholar : PubMed/NCBI
32	Wu X, Wang P, Zhang Y, Gao L, Zheng B, Xu Y and Mo J: Toll-like receptor characterization correlates with asthma and is predictive of diagnosis. DNA Cell Biol. 39:1313–1321. 2020. View Article : Google Scholar : PubMed/NCBI
33	Pandey RC, Michel S, Tesse R, Binia A, Schedel M, Liang L, Klopp N, Franke A, von Berg A, Bufe A, et al: Genetic variation in the toll-like receptor signaling pathway is associated with childhood asthma. J Allergy Clin Immunol. 131:602–605. 2013. View Article : Google Scholar : PubMed/NCBI
34	Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C, et al: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science. 282:2085–2088. 1998. View Article : Google Scholar : PubMed/NCBI
35	Gnad F, Baucom A, Mukhyala K, Manning G and Zhang Z: Assessment of computational methods for predicting the effects of missense mutations in human cancers. BMC Genomics. 14:1–13. 2013. View Article : Google Scholar
36	Pelham CJ, Pandya AN and Agrawal DK: Triggering receptor expressed on myeloid cells receptor family modulators: A patent review. Exp Opin Ther Pat. 24:1383–1395. 2014. View Article : Google Scholar : PubMed/NCBI
37	Sun H, Feng J and Tang L: Function of TREM1 and TREM2 in liver-related diseases. Cells. 9:26262020. View Article : Google Scholar : PubMed/NCBI
38	Liu Q, Johnson EM, Lam RK, Wang Q, Ye HB, Wilson EN, Minhas PS, Liu L, Swarovski MS, Tran S, et al: Peripheral TREM1 responses to brain and intestinal immunogens amplify stroke severity. Nat Immunol. 20:1023–1034. 2019. View Article : Google Scholar : PubMed/NCBI
39	Bernal-Martínez L, Gonçalves SM, de Andres B, Cunha C, Jimenez IG, Lagrou K, Mellado E, Gaspar ML, Maertens JA, Carvalho A and Alcazar-Fuoli L: TREM1 regulates antifungal immune responses in invasive pulmonary aspergillosis. Virulence. 12:570–583. 2021. View Article : Google Scholar : PubMed/NCBI
40	Chen B, Zhou M, Zhang H, Wang C, Hu X, Wang B and Wang E: TREM1/Dap12-based CAR-T cells show potent antitumor activity. Immunotherapy. 11:1043–1055. 2019. View Article : Google Scholar : PubMed/NCBI
41	Mlecnik B, Bindea G, Pagès F and Galon J: Tumor immunosurveillance in human cancers. Cancer Metastasis Rev. 30:5–12. 2011. View Article : Google Scholar : PubMed/NCBI
42	Ribas A: Adaptive immune resistance: How cancer protects from immune attackadaptive immune resistance. Cancer Discov. 5:915–919. 2015. View Article : Google Scholar : PubMed/NCBI
43	Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A and Peters S: Development of tumor mutation burden as an immunotherapy biomarker: Utility for the oncology clinic. Ann Oncol. 30:44–56. 2019. View Article : Google Scholar : PubMed/NCBI
44	Palucka AK and Coussens LM: The basis of oncoimmunology. Cell. 164:1233–1247. 2016. View Article : Google Scholar : PubMed/NCBI
45	Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, Sokol ES, Frampton G, Schrock AB, Anhorn R and Reddy P: Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: A review of current evidence. Oncologist. 25:e147–e159. 2020. View Article : Google Scholar : PubMed/NCBI
46	Cheng X, Wang X, Nie K, Cheng L, Zhang Z, Hu Y and Peng W: Systematic pan-cancer analysis identifies TREM2 as an immunological and prognostic biomarker. Front Immunol. 12:6465232021. View Article : Google Scholar : PubMed/NCBI